Gary Hardiman – författare
Visar alla böcker från författaren Gary Hardiman. Handla med fri frakt och snabb leverans.
9 produkter
9 produkter
Häftad, Engelska, 2023
1 567 kr
Skickas inom 10-15 vardagar
Environmental Contaminants and Endocrine Health focuses specifically on contaminants with hormonal disrupting activities. The book provides insights into the multiple effects of endocrine-disrupting chemicals (EDCs) and their mechanism of action (MoA) on metabolism, reproduction and the multiple physiological roles of the endocannabinoid system which has recently been indicated as new target. The content systematically covers EDC sources and effects, EDCs as sources of disease and health impairment in laboratory models, EDCs as the cause of disease and health impairment in humans and wild species, and the removal of hazardous pollutants from wastewaters to highlight intervention, mitigation and adaptation for reduced threat.
This content will be a foundational resource for academic and research staff in endocrinology and hormone toxicology as well as for professors, researchers and students in these areas.
Includes important foundational coverage of the endocrine system, definitions of EDC sources and descriptions, model examples and mechanisms of action biological effects Provides coverage of EDC effects in humans and animals, from metabolic alterations to epidemiological studies of fertility and metabolism Presents insights into the confirmed and suspected human diseases spectrum with origins linked to EDC exposure, including cancers, intellectual disabilities, autism, birth defects of the urethra (hypospadias), decreased sperm count, increased rates of miscarriage, obesity, type 2 diabetes, and more
E-bok
Engelska, 20232 229 kr
Läs direkt efter köp
Environmental Contaminants and Endocrine Health focuses specifically on contaminants with hormonal disrupting activities. The book provides insights into the multiple effects of endocrine-disrupting chemicals (EDCs) and their mechanism of action (MoA) on metabolism, reproduction and the multiple physiological roles of the endocannabinoid system which has recently been indicated as new target. The content systematically covers EDC sources and effects, EDCs as sources of disease and health impairment in laboratory models, EDCs as the cause of disease and health impairment in humans and wild species, and the removal of hazardous pollutants from wastewaters to highlight intervention, mitigation and adaptation for reduced threat.This content will be a foundational resource for academic and research staff in endocrinology and hormone toxicology as well as for professors, researchers and students in these areas.- Includes important foundational coverage of the endocrine system, definitions of EDC sources and descriptions, model examples and mechanisms of action biological effects- Provides coverage of EDC effects in humans and animals, from metabolic alterations to epidemiological studies of fertility and metabolism- Presents insights into the confirmed and suspected human diseases spectrum with origins linked to EDC exposure, including cancers, intellectual disabilities, autism, birth defects of the urethra (hypospadias), decreased sperm count, increased rates of miscarriage, obesity, type 2 diabetes, and more
Häftad, Engelska, 2019
990 kr
Skickas inom 10-15 vardagar
In recent years, high-density DNA microarrays have revolutionized biomedical research and drug discovery efforts by the pharmaceutical industry. Their efficacy in identifying and prioritizing drug targets based on their ability to confirm a large number of gene expression measurements in parallel has become a key element in drug discovery. Microarray Innovations: Technology and Experimentation examines the incredibly powerful nature of array technology and the ways in which it can be applied to understanding the genomic basis of disease.Explores a myriad of applications in use todayThis volume explores recent innovations in the microarray field and tracks the evolution of the major platforms currently used. The international panel of contributors presents a survey of the past five years’ research and advancements in microarray methods and applications and their usage in drug discovery and biomedical research. The contributions discuss improvements in automation (array fabrication and hybridization), new substrates for printing arrays, platform comparisons and contrasts, experimental design, and data normalization and mining schemes. They also review epigenomic array studies, electronic microarrays, comparative genomic hybridization, microRNA arrays, and mutational analyzes. In addition, the book provides coverage of important clinical diagnostic arrays, protein arrays, and neuroscience applications.Examines improved methodologiesAs microarrays have evolved steadily over time from archetypical in-house complementary DNA (cDNA) arrays to robust commercial oligonucleotide platforms, there has been a migration to higher density biochips with increasing content and better analytical methodologies. This compendium summarizes the vast advances that have been made in this technology, highlighting the supreme advantages of microarray-based appro
E-bok
Engelska, 20061 103 kr
Läs direkt efter köp
In the fiercely competitive pharmaceutical marketplace, your organization cannot afford to spend excess dollars developing drugs that will fail to get FDA approval or have profoundly poor characteristics. Biochips as Pathways to Drug Discovery takes a comprehensive look at how the industry faces these challenges, using new technologies such as bioc
E-bok
Engelska, 20091 136 kr
Läs direkt efter köp
In recent years, high-density DNA microarrays have revolutionized biomedical research and drug discovery efforts by the pharmaceutical industry. Their efficacy in identifying and prioritizing drug targets based on their ability to confirm a large number of gene expression measurements in parallel has become a key element in drug discovery. Microarr
E-bok
PDF, Engelska, 20061 103 kr
Läs direkt efter köp
In the fiercely competitive pharmaceutical marketplace, your organization cannot afford to spend excess dollars developing drugs that will fail to get FDA approval or have profoundly poor characteristics. Biochips as Pathways to Drug Discovery takes a comprehensive look at how the industry faces these challenges, using new technologies such as bioc
Inbunden, Engelska, 2009
2 673 kr
Skickas inom 10-15 vardagar
In recent years, high-density DNA microarrays have revolutionized biomedical research and drug discovery efforts by the pharmaceutical industry. Their efficacy in identifying and prioritizing drug targets based on their ability to confirm a large number of gene expression measurements in parallel has become a key element in drug discovery. Microarray Innovations: Technology and Experimentation examines the incredibly powerful nature of array technology and the ways in which it can be applied to understanding the genomic basis of disease.Explores a myriad of applications in use todayThis volume explores recent innovations in the microarray field and tracks the evolution of the major platforms currently used. The international panel of contributors presents a survey of the past five years’ research and advancements in microarray methods and applications and their usage in drug discovery and biomedical research. The contributions discuss improvements in automation (array fabrication and hybridization), new substrates for printing arrays, platform comparisons and contrasts, experimental design, and data normalization and mining schemes. They also review epigenomic array studies, electronic microarrays, comparative genomic hybridization, microRNA arrays, and mutational analyzes. In addition, the book provides coverage of important clinical diagnostic arrays, protein arrays, and neuroscience applications.Examines improved methodologiesAs microarrays have evolved steadily over time from archetypical in-house complementary DNA (cDNA) arrays to robust commercial oligonucleotide platforms, there has been a migration to higher density biochips with increasing content and better analytical methodologies. This compendium summarizes the vast advances that have been made in this technology, highlighting the supreme advantages of microarray-based appro
E-bok
PDF, Engelska, 20091 146 kr
Läs direkt efter köp
In recent years, high-density DNA microarrays have revolutionized biomedical research and drug discovery efforts by the pharmaceutical industry. Their efficacy in identifying and prioritizing drug targets based on their ability to confirm a large number of gene expression measurements in parallel has become a key element in drug discovery. Microarr
Inbunden, Engelska, 2006
929 kr
Skickas inom 5-8 vardagar
In the fiercely competitive pharmaceutical marketplace, your organization cannot afford to spend excess dollars developing drugs that will fail to get FDA approval or have profoundly poor characteristics. Biochips as Pathways to Drug Discovery takes a comprehensive look at how the industry faces these challenges, using new technologies such as biochips to reduce the cost of drug discovery and improve drug safety. The book explores the tools and skills required at each step of the discovery process when using biochips to determine biological outcomes.The authors provide an in-depth review of the clinical and pharmacogenomic relevance of biochips, ChIP-chip assays, and high-throughput approaches. They discuss how biochips are used to develop biomarkers in the drug discovery process, primarily for gene expression profiling and Single Nucleotide Polymorphism (SNP) analysis. The book includes coverage of experimental theory, quality control, clinical laboratory sampling considerations, database concepts, industrial laboratory design, and the analysis of the resultant large data sets. It discusses the application of biochips to the study of malaria, toxicogenomics, and SNPs, as well as intellectual property and market overviews. The book concludes with a comprehensive overview of how these chips are employed from early target discovery through preclinical toxicology and on through to pharmacogenomic and proof of concept studies in humans. Written in an easily accessible style, the breadth of coverage introduces the subject to those new to the field, while the depth of coverage forms a foundation for future work. The book gives you the knowledge required to leverage the technology into bona fide discoveries. Daniel E. Levy, editor of the Drug Discovery Series, is the founder of DEL BioPharma, a consulting service for drug discovery programs. He also maintains a blog that explores organic chemistry.